Supplemental Figure 7.
(A) Immunoblot analysis and (B) mRNA relative expression by qPCR of MYLK of GIST T1 cells transfected with non-target siRNA (control) or MYLK siRNA (MYLK knockdown) after 24h. (C,D) Protein Kinase A activity in (C) GIST T1 cells after 24h treatment of increasing doses of ML-7, or (D) in tumor lysates from PDGFRA D842V PDXs treated for 2 weeks with vehicle (Veh), ML-7 10 mg/Kg, or avapritinib 3 mg/kg, or a combination of both drugs (combo). (E,F) Immunoblot analysis of tumor lysates from PDGFRA D842V PDXs treated as above. PKA C: Protein Kinase cAMP-Activated Catalytic Subunit Alpha; P-MYLC S19: Phospho-myosin light chain 2 Ser 19 (Cell Signaling Technologies); P-MYL 9/12 T17/S18: Phospho-MLC-2 thr17/ser18 detects MLC-2A/MYL12B, MLC-2B/MYL12A, and MLC-2C/MYL9 (Invitrogen); MYLK: myosin light chain 2 (Cell Signaling Technologies).